Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.34 Insider Own33.43% Shs Outstand68.28M Perf Week1.47%
Market Cap195.12M Forward P/E- EPS next Y-0.47 Insider Trans-0.02% Shs Float46.89M Perf Month3.17%
Income-33.57M PEG- EPS next Q-0.11 Inst Own39.87% Short Float2.25% Perf Quarter1.47%
Sales0.00M P/S- EPS this Y-48.28% Inst Trans41.99% Short Ratio4.06 Perf Half Y100.72%
Book/sh1.05 P/B2.64 EPS next Y-10.23% ROA-34.47% Short Interest1.05M Perf Year13.06%
Cash/sh1.03 P/C2.68 EPS next 5Y- ROE-38.57% 52W Range0.97 - 4.00 Perf YTD106.72%
Dividend Est.- P/FCF- EPS past 5Y27.24% ROI-45.80% 52W High-30.75% Beta0.89
Dividend TTM- Quick Ratio14.55 Sales past 5Y0.00% Gross Margin- 52W Low185.57% ATR (14)0.25
Dividend Ex-Date- Current Ratio14.55 EPS Y/Y TTM10.15% Oper. Margin0.00% RSI (14)47.35 Volatility8.48% 9.44%
Employees25 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.40
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-68.88% Payout- Rel Volume0.26 Prev Close2.84
Sales Surprise- EPS Surprise-26.00% Sales Q/Q- EarningsMay 07 AMC Avg Volume259.79K Price2.77
SMA20-2.36% SMA50-7.81% SMA20030.76% Trades Volume66,965 Change-2.46%
Date Action Analyst Rating Change Price Target Change
Apr-12-23Initiated B. Riley Securities Buy $6
Nov-22-22Initiated SVB Leerink Outperform $6
Jun-03-19Initiated SVB Leerink Outperform $14
Jun-03-19Initiated Stifel Buy $20
Jun-03-19Initiated Needham Buy $18
Jun-03-19Initiated BMO Capital Markets Outperform $15
May-13-24 08:57AM
May-09-24 07:30AM
May-08-24 06:56AM
May-07-24 08:59PM
04:05PM Loading…
May-01-24 04:05PM
Apr-18-24 09:55AM
Apr-09-24 07:30AM
Apr-04-24 08:30AM
Apr-02-24 07:30AM
Mar-21-24 10:46AM
Mar-20-24 08:53PM
04:05PM Loading…
Mar-13-24 04:05PM
Feb-28-24 07:30AM
Feb-06-24 07:30AM
Jan-17-24 12:00PM
Jan-04-24 07:30AM
Dec-05-23 07:30AM
Nov-30-23 09:35AM
Nov-14-23 09:55AM
Nov-12-23 11:13AM
Nov-09-23 04:05PM
Nov-02-23 07:30AM
Nov-01-23 04:05PM
Oct-13-23 08:30AM
12:00PM Loading…
Oct-11-23 12:00PM
Sep-06-23 07:30AM
Aug-12-23 08:30AM
Aug-11-23 06:44AM
Aug-10-23 04:05PM
Aug-03-23 04:05PM
Aug-01-23 07:30AM
Jul-06-23 07:30AM
Jun-04-23 10:45AM
May-30-23 07:30AM
May-22-23 04:05PM
May-16-23 11:46AM
May-12-23 06:38AM
May-11-23 04:05PM
May-10-23 08:48AM
May-09-23 07:30AM
May-04-23 04:05PM
May-02-23 07:30AM
Apr-27-23 07:30AM
Apr-11-23 04:05PM
Mar-18-23 02:03AM
Mar-17-23 06:19AM
Mar-16-23 04:05PM
Mar-09-23 04:05PM
Mar-08-23 07:30AM
Mar-06-23 04:05PM
Feb-21-23 07:00AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-25-23 09:00AM
Jan-05-23 04:05PM
Dec-26-22 08:26AM
Dec-19-22 04:05PM
Nov-14-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 07:30AM
Nov-03-22 04:05PM
Oct-27-22 07:30AM
Sep-30-22 09:40AM
Sep-23-22 01:18AM
Sep-22-22 04:01PM
Sep-19-22 09:35AM
Sep-14-22 09:40AM
Sep-07-22 07:30AM
Aug-30-22 04:05PM
Aug-24-22 07:30AM
Aug-22-22 09:30AM
Aug-11-22 04:05PM
Aug-09-22 07:30AM
Aug-04-22 05:41PM
Jul-21-22 06:45AM
Jul-19-22 09:13AM
Jul-14-22 09:00AM
Jul-07-22 07:30AM
Jun-30-22 12:53PM
Jun-29-22 08:37AM
Jun-23-22 10:58AM
Jun-07-22 07:30AM
May-12-22 04:05PM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-13-22 04:25PM
Apr-11-22 08:00AM
Apr-07-22 08:00AM
Apr-05-22 04:25PM
Mar-23-22 03:25PM
Mar-22-22 07:30AM
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOOD JENNIFER LPresident & CEOMay 10 '24Option Exercise2.194,57810,026217,891May 14 04:51 PM
GOOD JENNIFER LPresident & CEOMay 10 '24Sale2.904,57813,276213,313May 14 04:51 PM
Delfini LisaChief Financial OfficerOct 11 '23Option Exercise0.512,2921,17136,686Oct 12 04:00 PM
Delfini LisaChief Financial OfficerOct 11 '23Sale2.027851,58635,901Oct 12 04:00 PM
Delfini LisaChief Financial OfficerSep 11 '23Option Exercise0.512,2911,17135,105Sep 13 04:06 PM
Delfini LisaChief Financial OfficerSep 11 '23Sale2.207111,56434,394Sep 13 04:06 PM
Delfini LisaChief Financial OfficerAug 11 '23Option Exercise0.512,2921,17133,496Aug 14 04:00 PM
Delfini LisaChief Financial OfficerAug 11 '23Sale2.366821,61032,814Aug 14 04:00 PM
Delfini LisaChief Financial OfficerJul 11 '23Option Exercise0.512,2921,17131,891Jul 12 04:29 PM
Delfini LisaChief Financial OfficerJul 11 '23Sale2.346871,60831,204Jul 12 04:29 PM
Simon FarrellChief Commercial OfficerJun 20 '23Option Exercise0.516,2503,19445,650Jun 21 04:00 PM
Delfini LisaChief Financial OfficerJun 12 '23Option Exercise0.512,2911,17130,209Jun 14 04:28 PM
Delfini LisaChief Financial OfficerJun 12 '23Sale2.646101,61029,599Jun 14 04:28 PM